TWi Biotechnology sees hints of success in anti-inflammatory approach to type 2 diabetes
This article was originally published in Scrip
The Taiwanese company TWi Biotechnology is having some success with an oral small-molecule IL-1beta inhibitor in the treatment of type 2 diabetes, Phase IIb data suggest.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.